Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: Findings from the Alzheimer's Disease Neuroimaging Initiative
- 30 June 2010
- journal article
- research article
- Published by Elsevier BV in NeuroImage
- Vol. 51 (2), 654-664
- https://doi.org/10.1016/j.neuroimage.2010.02.064
Abstract
No abstract availableKeywords
Funding Information
- Alzheimer's Disease Neuroimaging Initiative (U01 AG024904)
- National Institute on Aging
- National Institute of Biomedical Imaging and Bioengineering (NIBIB)
- Pfizer Inc.
- Wyeth Research
- Bristol-Myers Squibb
- Eli Lilly and Company
- GlaxoSmithKline, Merck & Co. Inc.
- AstraZeneca AB
- Novartis Pharmaceuticals Corporation
- Alzheimer's Association
- Eisai Global Clinical Development
- Elan Corporation plc
- Forest Laboratories
- Institute for the Study of Aging
- U.S. Food and Drug Administration
This publication has 62 references indexed in Scilit:
- Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: Findings from the Alzheimer's Disease Neuroimaging InitiativeNeuroImage, 2010
- Comparing 3 T and 1.5 T MRI for tracking Alzheimer's disease progression with tensor‐based morphometryHuman Brain Mapping, 2010
- Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCINeurobiology of Aging, 2009
- Optimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: An ADNI study of 515 subjectsNeuroImage, 2009
- Detection of amyloid in Alzheimer’s disease with positron emission tomography using [11C]AZD2184European Journal of Nuclear Medicine and Molecular Imaging, 2009
- Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI)NeuroImage, 2009
- Decreased cerebrospinal fluid Aβ42 correlates with brain atrophy in cognitively normal elderlyAnnals of Neurology, 2009
- FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer’s diseaseEuropean Journal of Nuclear Medicine and Molecular Imaging, 2009
- MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkersBrain, 2008
- Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐BAnnals of Neurology, 2004